Head-to-head evidence
insulin detemir vs UBT38006
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Insulin receptor (basal) · full Type 2 Diabetes pipeline
insulin detemir · Levemir
Marketed by Novo Nordisk
NCT00283751 · Phase 3 · completed
The study randomized 583 participants to insulin detemir or insulin glargine, but it was open-label rather than blinded. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
UBT38006
Developed by United Bio-Technology (Hengqin)
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: October 2026 · NCT07630233 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: insulin detemir's landscape · UBT38006's landscape